Share on StockTwits

Shares of Amedisys (NASDAQ:AMED) have received an average rating of “Hold” from the nine brokerages that are covering the stock, American Banking and Market News reports. One research analyst has rated the stock with a sell rating and six have given a hold rating to the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $12.50.

A number of research firms have recently commented on AMED. Analysts at RBC Capital raised their price target on shares of Amedisys from $7.00 to $10.00 in a research note on Friday, July 18th. They now have an “underperform” rating on the stock. Separately, analysts at Deutsche Bank upgraded shares of Amedisys from a “sell” rating to a “hold” rating in a research note on Monday, June 30th. They now have a $14.00 price target on the stock, up previously from $8.00. Finally, analysts at CRT Capital upgraded shares of Amedisys from a “sell” rating to a “fair value” rating in a research note on Friday, June 27th.

Amedisys (NASDAQ:AMED) traded up 1.39% on Tuesday, hitting $16.06. The stock had a trading volume of 30,144 shares. Amedisys has a one year low of $11.36 and a one year high of $18.70. The stock has a 50-day moving average of $15.11 and a 200-day moving average of $14.93. The company’s market cap is $527.0 million.

Amedisys (NASDAQ:AMED) last released its earnings data on Thursday, May 8th. The company reported ($0.07) earnings per share for the quarter, missing the analysts’ consensus estimate of $0.56 by $0.63. The company had revenue of $298.74 million for the quarter, compared to the consensus estimate of $301.89 million. During the same quarter last year, the company posted $0.13 earnings per share. Amedisys’s revenue was down 9.1% compared to the same quarter last year. Analysts expect that Amedisys will post $0.07 EPS for the current fiscal year.

Amedisys, Inc (NASDAQ:AMED) is a health care company focused on bringing home the continuum of care.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.